Additionally, MED19 can interact with EGFR and activates the EGFR/mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway, which in turn induces carcinogenesis and BC progression [78]. This evidence concerns the gene EGFR and breast cancer.